secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-05-22T20:55:24+00:00
Accession:  0001493152-26-025061
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq notifies Ensysce of delisting risk for equity shortfall
--------------------------------------------------------------

- Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
- Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.
- Company plans to submit a timely plan and explore options, but no assurance Nasdaq will accept or extension granted.
- Failure could lead to delisting; company may appeal to Nasdaq Hearings Panel if plan rejected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer